Follow-up Protocol to the Open-Label Phase 0 Part of the Phase II Opsona Study OPN-305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function) [EXTENSION OF 700236725]
Latest Information Update: 17 Oct 2014
At a glance
- Drugs Tomaralimab (Primary)
- Indications Delayed graft function; Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Opsona Therapeutics
- 02 Jul 2014 According to the European Clinical Trial Database record, status changed from recruiting to completed.
- 11 Sep 2013 New trial record